Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/CRD.0000000000000329 http://scihub22266oqcxt.onion/10.1097/CRD.0000000000000329 32769401!ä!32769401 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32769401&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cardiol+Rev 2020 ; 28 (5): 266-271 Nephropedia Template TP {{tp|p=32769401|t=2020. Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe?|pdf=|usr=}}{{32769401}} gab.com Text Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe JO: Cardiol Rev http://www.kidney.de/pget.php?&tw=1&pmid=32769401 #FOAvip Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a threat to the health of many humans across the world as they confront coronavirus disease 2019 (COVID-19). Previous promising in vitro data that emerged after the SARS-CoV outbreak in 2003, along with the emergent need for pharmacologic management strategies in the fight against COVID-19, prompted interest in the use of chloroquine and hydroxychloroquine across the globe. Unfortunately, the in vitro activity of these drugs did not necessarily correlate with most in vivo studies, which showed no consistent efficacy. Safety is also a major concern, with these agents having a known risk of QT prolongation and proarrhythmic effects. In addition, clinical practice guidelines provide no clear consensus on the role of chloroquine or hydroxychloroquine for the management of COVID-19. The United States Food and Drug Administration has declared that the potential benefits of these agents no longer outweigh the possible risks, and unless new emerging information suggests a more favorable risk:benefit ratio, neither chloroquine nor hydroxychloroquine should be recommended for COVID-19 treatment or prevention at this time. Twit Text FOAVip Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe ????Cardiol Rev http://www.kidney.de/pget.php?&tw=1&pmid=32769401 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32769401 #FOAvip English Wikipedia <ref>{{Cite pmid|32769401}}</ref> Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe? #MMPMID32769401 Schluenz LA; Ramos-Otero GP; Nawarskas JJ Cardiol Rev 2020[Sep]; 28 (5): 266-271 PMID32769401show ga Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to be a threat to the health of many humans across the world as they confront coronavirus disease 2019 (COVID-19). Previous promising in vitro data that emerged after the SARS-CoV outbreak in 2003, along with the emergent need for pharmacologic management strategies in the fight against COVID-19, prompted interest in the use of chloroquine and hydroxychloroquine across the globe. Unfortunately, the in vitro activity of these drugs did not necessarily correlate with most in vivo studies, which showed no consistent efficacy. Safety is also a major concern, with these agents having a known risk of QT prolongation and proarrhythmic effects. In addition, clinical practice guidelines provide no clear consensus on the role of chloroquine or hydroxychloroquine for the management of COVID-19. The United States Food and Drug Administration has declared that the potential benefits of these agents no longer outweigh the possible risks, and unless new emerging information suggests a more favorable risk:benefit ratio, neither chloroquine nor hydroxychloroquine should be recommended for COVID-19 treatment or prevention at this time. |Arrhythmias, Cardiac/*chemically induced[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Chloroquine/*therapeutic use[MESH] |Coronavirus Infections/*drug therapy[MESH] |Cytochrome P-450 CYP2D6/metabolism[MESH] |Drug Interactions[MESH] |Enzyme Inhibitors/*therapeutic use[MESH] |Humans[MESH] |Hydroxychloroquine/*therapeutic use[MESH] |In Vitro Techniques[MESH] |Long QT Syndrome/chemically induced[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy[MESH] |Practice Guidelines as Topic[MESH] |SARS-CoV-2[MESH] |Torsades de Pointes/chemically induced[MESH]Chloroquine or Hydroxychloroquine for Management of Coronavirus Diseas(epmc).pdf DeepDyve Pubget Overpricing